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Abstract
Background: Intrathecal lidocaine reverses tactile allodynia after nerve injury, but whether neuropathic pain is
attenuated by intrathecal lidocaine pretreatment is uncertain.
Methods: Sixty six adult male Sprague-Dawley rats were divided into three treatment groups: (1) sham (Group S),
which underwent removal of the L6 transverse process; (2) ligated (Group L), which underwent left L5 spinal nerve
ligation (SNL); and (3) pretreated (Group P), which underwent L5 SNL and was pretreated with intrathecal 2%
lidocaine (50 μl). Neuropathic pain was assessed based on behavioral responses to thermal and mechanical stimuli.
Expression of sodium channels (Nav1.3 and Nav1.8) in injured dorsal root ganglia and microglial proliferation/
activation in the spinal cord were measured on post-operative days 3 (POD3) and 7 (POD7).
Results: Group L presented abnormal behavioral responses indicative of mechanical allodynia and thermal
hyperalgesia, exhibited up-regulation of Nav1.3 and down-regulation of Nav1.8, and showed increased microglial
activation. Compared with ligation only, pretreatment with intrathecal lidocaine before nerve injury (Group P), as
measured on POD3, palliated both mechanical allodynia (p < 0.01) and thermal hyperalgesia (p < 0.001), attenuated
Nav1.3 up-regulation (p = 0.003), and mitigated spinal microglial activation (p = 0.026) by inhibiting phosphorylation
(activation) of p38 MAP kinase (p = 0.034). p38 activation was also suppressed on POD7 (p = 0.002).
Conclusions: Intrathecal lidocaine prior to SNL blunts the response to noxious stimuli by attenuating Nav1.3 up-
regulation and suppressing activation of spinal microglia. Although its effects are limited to 3 days, intrathecal
lidocaine pretreatment can alleviate acute SNL-induced neuropathic pain.
Background
Peripheral nerve injury caused by disease or surgery,
such as limb and colon amputation, nerve dissection,
mastectomy, and thoracotomy, often results in neuro-
pathic pain [1]. It is a neglected problem for which very
few patients are referred for surgical management [2].
Patients who develop postsurgical chronic neuropathic
pain suffer from acute postoperative pain and have
intraoperative nerve damage [3]. Nearly 50% of patients
with neuropathic pain receive inadequate pain relief,
and conventional analgesics are generally ineffective [4].
Systemic or regional analgesic treatment before tissue
damage occurs has proven effective for treating post-
operative pain [5-7]. Pre-incisional intraspinal adminis-
tration of local anesthetics inhibits nerve impulses in
response to noxious stimuli and reduces postoperative
morphine requirements [8]. Although treating injured
peripheral nerves with local anesthetic can inhibit neu-
ropathic pain [9,10], the effects of intrathecal lidocaine
pretreatment on neuropathic pain have not been
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pain correlates with the risk of developing a persistent
pain state [3], early therapy of acute postoperative pain
is important.
Lidocaine, the local anesthetic most commonly used in
clinical practice, confers anti-arrhythmic and nerve con-
duction-blocking effects by acting on voltage-gated
sodium channels. Intravenous administration of lido-
caine also alleviates the tactile allodynia associated with
neuropathic pain [11]. Intrathecal lidocaine after periph-
eral nerve injury reverses well-developed tactile allodynia
either through interaction with eicosanoid systems in
the spinal dorsal horn or by attenuating phosphorylation
of p38 mitogen-activated protein (MAP) kinase in acti-
vated microglia of the spinal cord [12-14]. However, the
use of intrathecal lidocaine pretreatment to attenuate
neuropathic pain is not a recognized therapeutic option.
A recent study in rodents found that intrathecal lido-
caine administration before injection of formalin into
the hindpaw suppresses nociceptive behavior and Fos
expression by diminishing central hyperexcitability [15].
Moreover, pretreatment with intrathecal injection of 4%
lidocaine delays the onset of neuropathic pain [16].
Nonetheless, pretreatment intrathecal lidocaine does not
reduce the incidence of autotomy after axotomy [17].
Although intrathecal low-dose lidocaine (100 μgi n1 0
μl) induces a transient, flaccid leg paralysis, it does not
prevent tactile hypersensitivity [18]. To elucidate the
potential of intrathecal lidocaine pretreatment for the
alleviation of postoperative neuropathic pain, we admi-
nistered intrathecal 2% lidocaine to mimic the clinical
use of regional anesthesia before surgery. The effective-
ness of intrathecal lidocaine pretreatment in reducing
neuropathic pain was evaluated by behavioral testing, by
measuring dysregulation of sodium channel a-subunit
(Nav1.3 and Nav1.8) expression in dorsal root ganglia
(DRGs), and by measuring spinal microglial activation in
the spinal cord. We found that intrathecal lidocaine pre-
treatment alleviated pain-related thermal hyperalgesia
and mechanical allodynia, attenuated up-regulation of
Nav1.3 in the injured DRG, and significantly reduced
spinal microglial activation on post-operative day 3
(POD3). The levels of phosphorylated (activated) p38
MAP kinase (p-p38) were also diminished on POD3 and
POD7. Therefore, intrathecal lidocaine administration
before peripheral nerve injury can attenuate neuropathic
pain for 3 days.
Methods
Experimental Animals and Groups
Sixty six adult male Sprague-Dawley rats weighting 300-
350 g were used in this study. The animals were housed
in plastic cages with soft bedding under a 12 h light-
dark cycle (light cycle from 6 am to 6 pm; dark cycle
from 6 pm to 6 am) with free access to food and water.
The rats were kept for at least 7 days under these condi-
tions before surgery. All experimental procedures were
approved by the Kaohsiung Institutional Animal Care
and Use committee. The rats were divided into three
experimental groups: (1) Sham (Group S, n = 22); ani-
mals in this group had their left sixth lumbar spine
transverse process surgically removed and received local
lidocaine on subcutaneous tissues and paraspinal mus-
cles, but were not subjected to spinal nerve ligation
(SNL) and received no intrathecal lidocaine. (2) Ligated
(Group L, n = 22); animals in this group were subjected
to surgery with SNL and received local lidocaine on
subcutaneous tissues and paraspinal muscles, but were
not administered intrathecal lidocaine. (3) Lidocaine
Pretreated (Group P, n = 22); animals in this group
were subjected to surgery with SNL and received local
lidocaine on subcutaneous tissues and paraspinal mus-
cles, and were also pretreated with intrathecal 2% lido-
caine. The animals were kept under the same conditions
throughout the study. All experimental rats underwent
thermal and mechanical pain tests (allodynia) 1 day
before surgery (pre-OP), and 3, 5, 7, 14, and 28 days
postoperatively (POD3,P O D 5,P O D 7,P O D 14,a n d
POD28, respectively).
Intrathecal Lidocaine Pretreatment
Before intrathecal lidocaine pretreatment, each rat was
handled by the operator to minimize stress-induced
analgesia. All animals were fully conscious during
intrathecal lidocaine injection. After optimal flexion of
the lumbar spine in the prone position, each rat received
a subcutaneous injection of 100 μl of 1.0% lidocaine into
the lumbar 4-5 (L4-5) intervertebral space. Next, 50 μlo f
1% lidocaine was injected into the right and left para-
spinal spaces to a depth of 0.5 cm, and 0.5 cm from the
mid-point of the longitudinal line of the L4-5 interver-
tebral space [19]. A 30 gauge needle attached to a 100
μl syringe (Hamilton, Reno, NV, USA) was inserted
intrathecally through the midline of the L4-5 interverteb-
ral space after local infiltrative anesthesia. After the nee-
dle was passed through the ligamentum flavum and the
dura mater, entry into the intrathecal space was con-
firmed by a change in resistance and movement of the
tail [19]. A 2% solution of lidocaine (50 μl, 1 mg total)
was administered. Rats showing of lower limbs paralysis
and without pain withdrawal response as application of
Adson forceps on lateral paws were included in group
P. Rats with unilateral blockades were excluded from
the analysis.
Induction of Neuropathic Pain by SNL
All surgical procedures were performed under isoflur-
ane/O2 anesthesia. With the animal placed in a prone
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spinous processes at the L4-S2 level. In Group S, the left
L6 transverse process was removed to expose the L4 and
L5 spinal nerves. In Groups L and P, the left L5 spinal
nerve was isolated and tightly ligated with 6-0 Dexon.
After complete hemostasis by light compression, the
wound was sutured with 3-0 silk thread. On the second
day after surgery, rats that dragged their feet during
movement were excluded from the analysis.
Behavioral Testing
Latency of foot withdrawal from a noxious heat stimulus
The latency of foot withdrawal from a noxious heat sti-
mulus was measured as described by Kim and Chung
[20]. Briefly, each rat was placed on a device consisting
of a light box with a glass plate on top (Model 7370
Plantar Test, Ugo Basile, Varese, Italy). Rats were
allowed to acclimatize to the environment. After cessa-
tion of exploratory behavior (typically 5-10 minutes), a
movable radiant heat generator was placed beneath the
glass floor. The glass plate was heated by a beam of
light projected through a hole (2 × 5 mm) in the light
box. A photocell automatically turned off the light when
it sensed that the rat had lifted its foot, allowing mea-
surement of the time between light-on and light-off. If
the rat did not react after 20 seconds, the heat source
was automatically switched off to avoid tissue damage.
T h et i m ef r o ma p p l i c a t i o no f the heat source to with-
drawal of the hindpaw was defined as the foot-withdra-
wal latency. Five minutes were allowed between
stimulations; withdrawal responses were measured five
times for each hindpaw and the average response time
was recorded. Spontaneous movements during heating
were not recorded. To ensure that the heat stimulus
remained at a constant intensity of 190 mv/m
2 through-
out the test, the device was calibrated with a Heat-Flux
I.R. Radiometer (Model 37300, Ugo Basile, Italy).
Latency of foot-withdrawal response to a mechanical
stimulus
Rats were first acclimatized to the mechanical stimulus-
testing environment, which was a metal mesh floor cov-
ered by a transparent plastic dome (8 × 8 × 18 cm). A
Dynamic Plantar Aesthesiometer (Ugo Basil, Italy) fila-
ment underneath the metal mesh was applied perpendi-
cular to the outer mid-plantar surface of the paw. The
filament controller was preset to a force of 50 g and a
duration of 20 seconds (increasing force from 0 to 50 g
in 20 seconds). An automated test machine was used to
apply a mechanical stimulus with a 2 mm diameter
metal rod in increments of 2.5 g/s to either hind paw
until an abrupt foot-withdrawal response was elicited,
which was considered the sensitivity threshold for that
paw. When rapid withdrawal of the paw was observed,
the duration and force intensity were recorded with
approximately 0.1 g sensitivity. Each measurement was
repeated five times at intervals of approximately 3 min-
utes for each hind paw. The paw-withdrawal threshold
was determined by averaging measurements. In each
animal, hindpaws were tested separately and alternately.
Measurement of Sodium Channels in DRGs by Western
Blotting
After surgery, left L5 DRGs were removed from Groups
La n dP .T h eL 5 DRG was also removed from the sham
group (Group S) to provide a normal control. For each
group (n = 8/group), DRGs were removed on POD3
(n = 4) and POD7 (n = 4).
Total cell proteins were homogenized and extracted
using RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl,
1 mM EDTA, 0.1% SDS, 1% NP-40, 0.5% sodium deoxy-
cholate), containing protease inhibitor cocktail (Roche,
Germany). Homogenates were centrifuged at 12,000
rpm for 20 minutes at 4°C, and the supernatant protein
concentration was determined using a Bio-Rad Protein
Assay Kit (Bio-Rad, USA). Total protein (50 μg) was
fractionated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis on 8% gels and blotted onto polyvi-
nylidene fluoride membranes (Millipore, MA, USA). Pri-
mary antibodies (rabbit anti-Nav1.3 and Nav1.8; Alomone
Labs, Jerusalem, Israel) were detected with horseradish
peroxidase-conjugated mouse anti-rabbit antibody
(Santa Cruz, Biotechnolog y ,S a n t aC r u z ,C A ,U S A ) .
Antibodies were detected using an enhanced chemilumi-
nescence western blotting detection and analysis system
(Amersham Biosciences, Tokyo, Japan). The density of
Nav1.3 and Nav1.8 bands were measured and normalized
to the density of the corresponding loading control (b-
actin). The Nav1.3 and Nav1.8 band-density values for
Groups L and P relative to those for Group S were cal-
culated on POD3 and POD7.
Tissue Preparation and Immunohistochemical Detection
of Microglia and p-p38 levels
Activation of microglia in the L5 spinal cord segment
following SNL was evaluated. Animals in Groups L, P
and S (normal controls) were anesthetized with thiopen-
tone 60 mg/kg and perfused with 0.9% saline followed
by 4% paraformaldehyde in 0.1 M phosphate buffer (pH
7.4). For each group (n = 6/group), L5 spinal cords were
removed on POD3 (n = 3) and POD7 (n = 3). Dissected
tissues were then fixed in 4% paraformaldehyde and
saturated in 10%-30% sucrose in 0.01 M phosphate-buf-
fered saline (pH 7.4). After embedding the tissues in O.
C.T. compound, 12 μm sections were cut with a cryostat
and mounted on glass slides for immunostaining.
Microglia proliferation in the spinal cord was assessed
immunohistochemically using a mouse monoclonal anti-
OX-42 primary antibody (mouse anti-rat-CD11b, 1:80,
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conjugated goat anti-mouse IgG secondary antibody
(Invitrogen, UK). Microglial activation was evaluated
using anti-p-p38 (1:200; Cell Signaling, Beverly, MA,
USA) as a primary antibody and Cy3-conjugated goat
anti-rabbit IgG as a secondary antibody. Control experi-
ments were performed without primary antibody and
yielded only background levels of signal. The immunor-
eactivity of sections was examined and images were cap-
tured with an Olympus LSM5 fluorescence microscope.
Immunofluorescence staining in the spinal cord was
quantified by measuring microglia- and p-p38-positive
staining areas in the ipsilateral dorsal horn of each sec-
tion using a computerized image-analysis system. The
background fluorescence intensity of each tissue section
was also determined and subtracted from the values
obtained. Fluorescence intensities exceeding this back-
ground were considered true intensities. Six sections
were measured in each rat, and the average density of
microglia and the intensity of p-p38 staining were deter-
mined for each group.
Double-Immunofluorescence Labeling
For double-immunofluorescence labeling, sections were
incubated for 48 hours at 4°C with a mixture of anti-p-
p38 MAPK antibody (1:100) and mouse monoclonal
anti-OX-42 antibody (CD11b, 1:100; Serotec, Indianapo-
lis, USA). Cy3- or Alexa Fluor 488- conjugated second-
ary antibodies were used as appropriate to visualize
bound primary antibodies. The stained sections were
examined with a fluorescence microscope, and images
were captured with a CCD spot camera.
Histological Staining
L5 spinal cord specimens were collected, fixed in 10%
neutral-buffered formalin for several hours and
embedded in paraffin. 3-4 μm sections were cut, stained
with hematoxylin and eosin (H&E) and viewed under a
light microscope.
Statistical Analysis
Differences in western blotting among groups were
assessed by one-way ANOVA, followed by Scheffe’s test
for multiple post hoc analyses where appropriate. Com-
parisons of behavioral responses, microglia proliferation,
and p-p38 activation among groups were performed
using Mann-Whitney U tests. SPSS 15.0 software (SPSS,
NY, USA) was used for all statistical analyses, and a P-
value < 0.05 was considered statistically significant. Spe-
cific significance levels are indicated in figure legends.
Results
None of the animals exhibited autotomy, body-weight
loss, ventroflexion, or dragging of the hind paw during
forward movement. In Group S, immunohistochemical
staining results from ipsi- and contralateral sides were
statistically indistinguishable, and there were no signifi-
cant differences between left and right hind paws in
behavioral tests. Abnormal histopathological responses
to intrathecal lidocaine, including obvious demyelination
of spinal root or inflammatory cell infiltration into the
spinal cord, were absent in all rats.
Behavioral testing
Figure 1A shows differences in withdrawal threshold to a
mechanical stimulus between left and right paws. The
average baseline withdrawal threshold forces for left/right
paw were 33/33.4 g in Group S, 34.9/35.6 g in Group L
and 34.3/35.1 g in Group P. Throughout the study, all
measurements of right paw withdrawal remained in the
28-36 g range. The difference in force-induced withdra-
wal thresholds between hindpaws (mechanical allodynia)
increased significantly in Group L; intrathecal lidocaine
pretreatment shortened the difference during the first 3
days (P < 0.01, Group L vs. P). Figure 1B shows the dif-
ferences in withdrawal threshold to thermal stimuli
between left and right paws. The average baseline ther-
mal withdrawal thresholds for left/right hindpaws were
11.0/11.2 seconds in Group S, 10.8/11.0 seconds in
Group L, and 10.9/10.8 seconds in Group P. In Group L,
withdrawal latency of the left hindpaw was shortened
after SNL; intrathecal lidocaine pretreatment blunted the
responses on POD3 (P < 0.001, Group L vs. P).
SNL modulated Nav1.3 and Nav1.8 expression in injured
DRGs
SNL dysregulated DRG sodium channel expression in
injured DRGs, up-regulating Nav1.3 and down-regulating
Nav1.8. Compared with the ligated-only group, intrathe-
cal lidocaine pretreatment reduced Nav1.3 up-regulation
on POD3 (p =0 . 0 0 3 )b u tn o to nP O D 7 (p =0 . 3 6 ;
Figure 2). However, intrathecal lidocaine pretreatment
had no significant effect on Nav1.8 down-regulation.
Increased proliferation and activation of microglia in the
spinal cord after SNL
SNL induced an increase the activation status of residual
microglia in the spinal cord, as evidenced by increased
OX-42 expression and increased p-p38 immunoreactiv-
ity. In Group S, low levels of OX-42 immunoreactivity
i nt h es p i n a lc o r dw e r eo b s e r ved (Figure 3A). Multiple
activated microglia were observed in the ipsilateral dor-
sal horn of the spinal cord after SNL, as shown in Fig-
ure 3B (POD3; p = 0.004) and 3D (POD7; p =0 . 0 0 8 ) .
Many activated microglia in Group L were p-p38 immu-
nopositive after nerve injury. Compared with Group S,
which showed low basal levels of p-p38, Group L exhib-
ited a higher intensity of p-p38 staining in the L5
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Group S vs. L), which was further increased on POD7
(Figure 4D; p = 0.005, Group S vs. L). Double-immuno-
fluorescence labeling with OX-42 (for microglia) and p-
p38 (for activated microglia) revealed colocalization of
p-p38 and OX-42 (i.e., dual-immunopositive cells) in the
spinal cord (Figure 4G).
Intrathecal lidocaine pretreatment reduced
microglial proliferation and activation (p-p38
levels) in the spinal cord
Compared with ligation only, intrathecal lidocaine pre-
treatment decreased the intensity of OX-42 immunor-
eactivity in the left spinal dorsal horn on POD3 (Figure
3C; p = 0.026), but not on POD7 (Figure 3E; p =0 . 2 8 9 ) .
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Figure 1 Intrathecal lidocaine pretreatment attenuated neurobehavioral responses to thermal and mechanical stimuli. (A) Mechanical
responses. Comparison of mean paw withdrawal in response to a mechanical stimulus (F = 50 g; T = 20 seconds) between ipsilateral (left) and
contralateral (right) sides in each group. Differences in mean paw withdrawal thresholds between hindpaws were significantly higher in Group L
than in Group P on POD3 (**P< 0.01). (B) Hyperalgesic responses. On POD3, the difference in mean withdrawal threshold between left and right
hindpaws was significantly larger (☆P< 0.001) in Group L than in Group P. Mean withdrawal thresholds did not significantly differ between left
and right hindpaws in Group S. Data represent means ± SE.
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Figure 2 Western blot showing that intrathecal lidocaine pretreatment decreased Nav1.3 up-regulation in injured DRGs after SNL (A).
Quantification of Nav1.3 band densities showed Nav1.3 expression was up-regulated after SNL, but was decreased on POD3 in Group P (C).
Western blot and quantification of Nav1.8 band densities showing that intrathecal lidocaine pretreatment did not reduce Nav1.8 down-regulation
in Group P (B, D). (*p < 0.05, **p < 0.01, ☆P< 0.001, NS: not statistically significant; ANOVA with post hoc Scheffe’s test.)
Left dorsal horn
A
S
B
L POD3
C
P POD3
D
L POD7
E
P POD7
POD3 POD7
F
0
500
1000
1500
2000
2500
SLPL  P
I
n
t
e
n
s
i
t
y
 
o
f
 
m
i
c
r
o
g
l
i
a
 
i
n
 
s
p
i
n
a
l
 
c
o
r
d
** *
**
NS
Figure 3 Intrathecal lidocaine pretreatment suppressed microglia-specific immunoreactivity induced by SNL in the spinal cord. Group
S showed weak immunoreactivity of the microglial marker OX-42 in the left dorsal horn (A). In Group L, SNL induced a significant increase in
microglia immunoreactivity in the ipsilateral spinal cord on POD3 (B) and POD7 (D). Intrathecal lidocaine pretreatment (Group P) decreased
microglia immunoreactivity on POD3 (C) but not on POD7 (E). Data represent means ± SE (*p < 0.05, **p < 0.01, NS: not statistically significant;
Mann-Whitney U test). Scale bars, 200 μm.
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lower on both POD3 (Figure 4C; p =0 . 0 3 4 )a n dP O D 7
(Figure 4E; p = 0.002). Taken together, these results
indicate that intrathecal lidocaine pretreatment before
SNL reduced activation of spinal microglia, as evidenced
by decreased OX-42 immunoreactivity and decreased
p-p38 levels.
Discussion
A single intrathecal injection of lidocaine, a standard
regional anesthetic procedure, is routinely performed in
lower limb surgery patients. It provides a stable hemo-
dynamic state during surgery, promotes smooth recov-
ery and attenuates immediate postoperative pain.
However, there is no consensus on the use of intrathecal
lidocaine pretreatment for patients with nerve damage
who require surgery.
The tetrodotoxin-sensitive sodium channel, Nav1.3,i s
expressed only during early stages of development and
is difficult to detect in the nervous system of adult rats.
After peripheral axotomy, Nav1.3 expression in injured
DRG neurons may increase within 8 hours, resulting in
a reduced action potential threshold and/or a relatively
high firing frequency [21]. In this study, intrathecal lido-
caine pretreatment inhibited Nav1.3 expression in
injured DRGs on POD3.T h i sr e s u l ti sc o n s i s t e n tw i t h
studies of pain-related behavior, which have shown a
positive correlation between increased Nav1.3 expression
in injured DRGs and peripheral nerve axotomy.
Increased Nav1.3 expression in axotomized DRG
neurons shifts the threshold to a more hyperpolarized
overshooting action potential that requires less depolari-
zation for activation and boosts ramp currents [22]; the
rate of recovery from inactivation is also accelerated in
injured neurons [23]. However, intrathecal administra-
tion of Nav1.3 specific antisense oligonucleotides, which
reduces DRG immunoreactivity by 50%, does not
attenuate mechanical or cold allodynia [24]. Moreover,
neuropathic pain behavior is unaffected in global and
conditional Nav1.3 knockout mice [25]. These reports
indicate that increased Nav1.3 expression does not sub-
stantially affect the behavioral hypersensitivity of injured
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Figure 4 Intrathecal lidocaine pretreatment moderated the increase in p-p38 immunoreactivity induced by SNL. Group S exhibited weak
p-p38 immunoreactivity in the left dorsal horn (A). In Group L, p-p38 immunoreactivity was significantly increased in the left dorsal horn on
POD3 (B) and on POD7 (D). Intrathecal lidocaine pretreatment (Group P) decreased SNL-induced p-p38 immunoreactivity on POD3 (C) and POD7
(E). Quantification of p-p38 immunoreactivity revealed significant increases on POD3 and POD7 after SNL. Intrathecal lidocaine pretreatment
reduced p-p38 immunoreactivity after SNL (F). Merged images from OX-42 (green) and p-p38 (red) in the ipsilateral L5 spinal cord on POD3
showed p-p38 colocalization with OX-42 (G). Data represent means ± SE (*p < 0.05, **p < 0.01; Mann Whitney U test). Scale bars, 200 μm (A-E)
and 50 μm (G).
Cheng et al. BMC Neurology 2011, 11:71
http://www.biomedcentral.com/1471-2377/11/71
Page 7 of 9nerves. Further study is needed to demonstrate whether
Nav1.3 plays a substantial role during neuropathic pain.
Peripheral nerve injury induces profound changes in
microglia, including hypertrophy, proliferation and up-
regulation of cell surface markers; it also modulates pain
signals in the dorsal horn and induces neuropathic pain
[26]. Blocking microglial activity and inhibiting micro-
glial proliferation are both effective in preventing or
delaying neuropathic pain [27,28]. Although the exact
roles of activated spinal microglia and neurons in pain
processing are still undetermined, an increase in p-p38
levels in activated microglia after peripheral nerve injury
i sr e p o r t e dt ob eam a j o rc a u s eo fh y p e r s e n s i t i v i t yt o
pain [28-30]. Intrathecal administration of lidocaine
after peripheral nerve injury is known to reverse well-
developed tactile allodynia [14]. A rat model of chronic
constriction injury also indicated that lidocaine reverses
tactile allodynia by attenuating phosphorylation of p38
in spinal cord microglia [12]. In the current study, rats
pretreated with intrathecal lidocaine exhibited decreased
spinal microglia activation on POD3 and diminished p-
p38 levels on POD3 and POD7 after SNL. This indicates
that the pretreatment reduces neuropathic pain not only
by inhibiting the proliferation of spinal microglia, but
also by reducing spinal microglial activity through a
decrease in p38 phosphorylation.
Although the Nav1.8 has important roles in both nor-
mal pain function and inflammatory pain, in this study,
Nav1.8 expression in injured DRGs was reduced after
nerve axotomy. Rat models of neuropathic pain asso-
ciated with axotomy reveal a substantial reduction in
Nav1.8 mRNA and protein levels in injured DRG neu-
rons [31,32]. However, specific knockdown of Nav1.8 by
intrathecal administration of an antisense oligodeoxynu-
cleotide is reported to exert anti-allodynic and anti-
hyperalgesic actions following SNL [33]. A potent and
highly selective Nav1.8 channel inhibitor has been shown
to block spontaneous and evoked action potentials in
injured DRG neurons [34]. Therefore, measuring expres-
sion of Navs in the vicinity of injured DRGs could be an
effective method for assessing neuropathic pain.
In the present study, lidocaine (2 mg) was locally
applied to L4-5 subcutaneous tissues and vertebral para-
spinal muscles to provide pain relief and to prevent rats
from moving during lumbar intrathecal lidocaine injec-
tion. But the ability of systemically absorbed lidocaine to
attenuate neuropathic pain following local injection is a
matter of debate. In rats, lidocaine administered intrave-
nously at doses of 1, 4 or 10 mg/kg did not abolish or
diminish brain activity in response to innocuous or nox-
ious stimulation. In fact, intravenous doses of 4 and 10
mg/kg lidocaine have been shown to enhance sensory
cortex responses to acute nociceptive stimulation,
increasing the activated cortical volume by 50%-60%
[35]. A large lidocaine intravenous dose (10 mg/kg bolus
in 3 minutes, followed by 180 μg/kg/min for 1 hour)
provides relief from neuropathic pain induced by
chronic constriction of the sciatic nerve [36]. Further-
more, local application of lidocaine to incisional skin
and exposed spinal nerves has been demonstrated to
attenuate postoperative peri-incisional skin allodynia
[37]. But the site of local lidocaine infiltration in the
present study was away from incised skin and no lido-
caine was applied to spinal nerves. Therefore, the dose
of local lidocaine injected into L4-5 subcutaneous tissue
and infiltrated into paraspinal muscles should not ame-
liorate L5 SNL-induced allodynia and hyperalgesia.
Conclusions
Peripheral nerve injury caused by trauma or surgery
may up-regulate Nav1.3 and down-regulate Nav1.8 in
injured DRGs, and activate spinal microglia, as evi-
denced by increased levels of phosphorylated p38 in the
spinal cord. A consequence of this dynamic is the devel-
opment of neuropathic pain. Intrathecal lidocaine pre-
treatment alleviates neuropathic pain by modulating
Nav1.3 expression and decreasing spinal microglial acti-
vation. Although the effect of intrathecal lidocaine pre-
treatment in this animal model of spinal nerve injury
was limited to 3 days, this treatment has excellent
potential for treating immediate neuropathic pain.
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